MS-553 not checked
MingSight Pharmaceuticals, Inc
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema, Diabetic Retinopathy
- Main trialPhase 1/2
- “A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma”In the company’s words, NCT06979076 on ClinicalTrials.gov
Other drugs for CLL (Chronic Lymphocytic Leukemia)
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- VenetoclaxAbbVie · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TacabrutidegBeOne Medicines (BeiGene) · Phase 3
- AcalabrutinibAstraZeneca · Phase 3
Coming up1
- Sep 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | Sep 2028 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | |
| Phase 1Recruiting | 30 Oct 2026 | MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema | |
| Phase 1/2Terminated | 28 Nov 2023 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | |
| Phase 1/2Terminated | 28 Nov 2023 | A Study Of The Selective PKC-β Inhibitor MS- 553 | |
| Phase 1/2Terminated | 28 Nov 2023 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026